The acute influence of vasopressin on hemodynamic status and tissue oxygenation following the Norwood procedure

Ronald A. Bronicki, MD, Sebastian Acosta, PhD, Fabio Savorgnan, MD, Saul Flores, MD, Barbara-Jo Achuff, MD, Rohit Loomba, MD, Mubbasheer Ahmed, MD, Nancy Ghanayem, MD, MS, Jeffrey S. Heinele, MD, Vicken Asadourian, BS, and Javier J. Lasa, MD

ABSTRACT

Objectives: Arginine vasopressin (AVP) is used to treat hypotension. Because AVP increases blood pressure by increasing systemic vascular resistance, it may have an adverse effect on tissue oxygenation following the Norwood procedure.

Methods: Retrospective analysis of continuously captured hemodynamic data of neonates receiving AVP following the Norwood procedure.

Results: We studied 64 neonates exposed to AVP within 7 days after the Norwood procedure. For the entire group, AVP significantly increased mean blood pressure (2.5 ± 6.3) and cerebral and renal oxygen extraction ratios (4.1% ± 9.6% and 2.0% ± 4.7%, respectively; P < .001 for all values). In the right ventricle to pulmonary artery shunt cohort, AVP significantly increased blood pressure, arterial oxygen saturation (1.4% ± 3.8%; P = .011), pulmonary to systemic perfusion ratio (0.2 ± 0.4; P = .017), and cerebral and renal oxygen extraction ratios (4.6% ± 8.7%; P = .010 and 4.7% ± 9.4%; P = .014, respectively). The Blalock-Taussig shunt cohort experienced a less significant vasopressor response and no change in arterial oxygen saturation, pulmonary to systemic perfusion ratio, or cerebral and renal oxygen extraction ratios.

Conclusions: The right ventricle to pulmonary artery shunt cohort experienced a significant vasopressor response to AVP that was associated with a significant increase in pulmonary perfusion and decrease in cerebral and renal perfusion, whereas the Blalock-Taussig shunt cohort experienced a less significant vasopressor response and no change in pulmonary or systemic perfusion. The influence of AVP on tissue oxygenation following the Norwood procedure may have clinical implications that require further study. (JTCVS Open 2022;9:217-24)

CENTRAL MESSAGE

Following the NP, we found AVP induced a significant vasopressor response in those patients who received a RVPAS, which was associated with a significant increase in pulmonary perfusion and decrease in systemic perfusion.

PERSPECTIVE

The optimal vasoactive strategy following the NP is not known. No study thus far has evaluated the influence of AVP on pulmonary and systemic perfusion. In those patients who underwent RVPAS insertion, AVP induced a significant vasopressor response, which was associated with a significant increase in pulmonary perfusion and decrease in systemic perfusion.

See Commentary on page 225.
Neonates with single-ventricle variants and obstruction to systemic blood flow may undergo the Norwood procedure (NP), which includes reconstruction of the diminutive aorta, placement of either a modified Blalock-Taussig shunt (BTS), or right ventricle to pulmonary artery shunt (RVPAS) and an atrial septectomy. Over the past several years, arginine vasopressin (AVP) has been increasingly used following the NP to treat hypotension while limiting expansion of intravascular volume and increases in heart rate (HR). However, because AVP increases arterial blood pressure (BP) by increasing systemic vascular resistance (SVR), it may have an adverse effect on stroke volume and cardiac output (CO). Further, because systemic and pulmonary circulations are in parallel, increasing SVR and systemic arterial BP may have an adverse effect on the distribution of total CO, increasing pulmonary perfusion (Qp) at the expense of systemic perfusion (Qs). Based on these theoretical concerns, we conducted a retrospective analysis of continuously captured physiologic data to provide a high-fidelity assessment of the acute influence of AVP on hemodynamic status and tissue oxygenation following the NP.

\[ \text{Abbreviations and Acronyms} \]

| Abbreviation | Definition |
|--------------|------------|
| ANOVA        | analysis of variance |
| AVP          | arginine vasopressin |
| BP           | blood pressure |
| BTS          | Blalock-Taussig shunt |
| CAP          | common atrial pressure |
| CO           | cardiac output |
| CPP          | coronary perfusion pressure |
| HR           | heart rate |
| NIRS         | near infrared spectroscopy |
| NP           | Norwood procedure |
| O2ER         | oxygen extraction ratio |
| PVR          | pulmonary vascular resistance |
| Qp           | pulmonary perfusion |
| Qs           | systemic perfusion |
| RVPAS        | right ventricular to pulmonary artery shunt |
| SaO2         | arterial oxygen saturation |
| SS           | steady state |
| SVR          | systemic vascular resistance |
| TSS          | time to steady state |
| VIS          | vasoactive infusion score |

The potential influence of confounding therapies administered during the TSS or SS periods on BP was analyzed. We chose the following potential confounders a priori: alterations in vasoactive support (utilizing the modified VIS), boluses of 5% albumin or normal saline, and boluses of September 1, 2014, through May 1, 2021. The indication for AVP was persistent hypotension despite volume administration and existing vasoactive support.

**AVP Infusion and Study Epochs**

Data were evaluated according to the following epochs: 1 hour before initiation of the AVP infusion, which established baseline hemodynamic parameters; the hour following the initiation of drug which, based on the 10- to 15-minute half-life of AVP, represented the time to steady state (TSS); and the second hour (ie, 60-120 minutes) following the initiation of AVP, which represented the steady state (SS). The subsequent re-initiation of AVP infusions were also studied, which required an additional initial hour following discontinuation of the infusion, allowing for complete clearance of AVP before analyzing the aforementioned epochs.

**Hemodynamic Parameters Data Extraction**

The Sickbay platform (Medical Informatics Corporation) was used to continuously capture hemodynamic data at a frequency of 0.5 Hz from bedside patient monitors (GE B850 monitors) and included HR, systolic BP, diastolic BP, mean BP, and common atrial pressure (CAP). The coronary perfusion pressure (CPP = diastolic BP – CAP) was also calculated. The physiological signals are time synchronized, stored onsite, and made available for analysis. Data analysis was completed using MATLAB (MathWorks).

**Oximetric Data Extraction**

Arterial pulse oximetry oxygen saturations (SaO2) were continuously captured at a frequency of 0.5 Hz and stored on the Sickbay platform. All patients following cardiac surgery are monitored with the Medtronic INVOS 7100 near infrared spectroscopy (NIRS) oximeter (Medtronic); however, intermittent connectivity between the INVOS monitor and the Sickbay platform for a minority of patients led to incomplete data capture. NIRS oxygen saturations were captured at a frequency of 0.2 Hz and stored on the Sickbay system. Qp to Qs ratio (Qp:Qs) was calculated using an assumed pulmonary venous oxygen saturation of 99% and the cerebral NIRS oxygen saturation was used for the central venous oxygen saturation.

**Hemodynamic Parameter and Oximetric Data Analysis**

The baseline, TSS and SS time periods were divided into 15-minute blocks to calculate a moving average for each hemodynamic and oximetric parameter. The TSS and SS averages were then compared with the baseline averages for each patient and each physiological parameter using paired t tests. This statistical design ensures that each patient serves as his or her own control. The association between 2 different physiological parameters was established using Kendall’s correlation analysis.

**Modified Vasoactive-Inotropic Score**

A modified vasoactive-inotropic score (VIS) was used to assess changes in concurrent vasoactive infusions. The VIS was modified to exclude AVP: 100 × epinephrine infusion rate plus 10 × milrinone infusion rate plus 100 × norepinephrine infusion rate (µg/kg/min).\( ^{10} \) Dopamine was excluded from the modified VIS based on institutional practice. An average modified VIS was determined for baseline, TSS and SS time periods. The change in VIS was analyzed using a repeated measures analysis of variance (ANOVA).

**Materials and Methods**

This study was conducted under an institutional review board protocol (No. H-40094), which was approved by the Baylor College of Medicine on November 30, 2016. The need for written consent was waived. Retrospective electronic medical records were obtained for each patient who received AVP in the cardiac intensive care unit within 7 days following the NP from March 2022.
calcium. These confounding therapies were categorized as binary variables, depending on whether or not they were administered during the AVP infusion. The relationship between confounders and BP response was assessed using ANOVA analysis. The relationships between AVP dose (low vs high dose, defined as < or ≥ 0.0003 U/kg/min) and BP response, and between initial and reinitiated AVP doses and BP response were assessed using ANOVA analysis.

AVP infusions were excluded in the case that a blood transfusion was initiated during the TSS or SS. Eleven AVP infusions were excluded due to concomitant blood cell transfusions. An AVP infusion that was associated with a delayed sternal closure occurring during any of the time periods was excluded. All patients were on a continuous infusion of calcium to maintain an ionized calcium of >1.3 mmol/L. All patients were on fentanyl and dexmedetomidine infusions, which were titrated according to unit protocol to achieve a negative state behavioral score scale of –1 to –2.

RESULTS

Patient Demographic Characteristics and AVP Exposures

A total of 135 patients underwent the NP during the study period, of which 64 were treated with AVP during the first 7 postoperative days. The median weight and age at the time of surgery was 3.3 kg (interquartile range [IQR], 3.00-3.60 kg) and 8.3 days (IQR, 4.7-10.8 days), respectively. Anatomic subtypes for the 64 patients included 59 patients with hypoplastic left heart syndrome, 3 patients with double outlet right ventricle with systemic outflow obstruction, 1 patient with right dominant atroventricular canal with systemic outflow obstruction, and 1 patient with a systemic left ventricle (double inlet left ventricle with systemic outflow obstruction). Amongst NP patients exposed to AVP, 33 underwent RVPAS insertion (52%), and 31 underwent BTS insertion (48%). For patients undergoing RVPAS insertion, 82% (n = 27) received a 6-mm diameter shunt, whereas 15% (n = 5) received a 5-mm shunt and 3% (n = 1) a 4-mm shunt. For those patients undergoing a BTS, 81% (n = 25) patients received a 3.5-mm diameter shunt, whereas 13% (n = 4) received a 4.0-mm shunt, and 6% (n = 2) a 3.0-mm shunt.

The 64 patients were exposed to 142 AVP infusions, of which 64 were initial infusions and 78 reinitiated infusions in the same patient. Of the 142 infusions, 76 infusions had cerebral NIRS oximetry monitoring and 72 infusions had renal NIRS oximetry monitoring. The initial infusion was initiated at a median time following surgery of 1.0 day (IQR, 0.2-3.4 days), with a majority of AVP infusions occurring during the first 2 postoperative days. The average AVP infusion dose over the 2-hour study period was 0.0002 U/kg/min for 90 infusions (63%), 0.0003 U/kg/min for 36 infusions (25%) and 0.0004 U/kg/min or greater for the remaining infusions (n = 16 [12%]).

Baseline Hemodynamic Parameter Data

The baseline hemodynamic parameters for the entire cohort and according to shunt type are listed in Table 1.

| Parameter | Entire cohort | RVPAS | BTS | Comparison | P value* |
|-----------|--------------|-------|-----|------------|---------|
| mBP (mm Hg) | 48.4 ± 7.3 | 50.5 ± 7.5 | 46.3 ± 6.8 | <.001 |
| sBP (mm Hg) | 68.3 ± 11.6 | 67.3 ± 10.6 | 68.9 ± 13.6 | .599 |
| dBP (mm Hg) | 36.8 ± 7.0 | 41.2 ± 6.6 | 32.6 ± 4.9 | <.001 |
| CAP (mm Hg) | 8.7 ± 2.4 | 9.0 ± 2.4 | 8.4 ± 2.4 | .189 |
| CPP (mm Hg) | 27.8 ± 6.4 | 31.7 ± 5.9 | 24.2 ± 5.1 | <.001 |
| Sato2 (%) | 82.7 ± 4.9 | 81.9 ± 5.3 | 83.5 ± 5.0 | .048 |
| Qp:Qs | 1.2 ± 0.6 | 1.1 ± 0.7 | 1.2 ± 0.7 | .286 |
| CO2ER (%) | 41.2 ± 14.4 | 40.9 ± 15.8 | 41.3 ± 13.6 | .802 |
| rO2ER (%) | 32.4 ± 15.6 | 33.3 ± 17.6 | 31.3 ± 14.9 | .754 |

Values are presented as mean ± SD. RVPAS, Right ventricular to pulmonary artery shunt; BTS, Blalock-Taussig shunt; HR, heart rate (bpm); mBP, mean blood pressure; sBP, systolic blood pressure; dBP, diastolic blood pressure; CAP, common arterial pressure; CPP, coronary perfusion pressure; Sato2, arterial oxygen saturation; Qp:Qs, pulmonary blood flow to systemic blood flow ratio; CO2ER, cerebral oxygen extraction ratio; rO2ER, renal oxygen extraction ratio. *P values are computed using the 2-sample t test to compare the RVPAS and BTS groups.

The BTS cohort had a significantly lower diastolic BP, and as result mean BP and CPP than the RVPAS cohort.

BP Response

Figure 1 demonstrates the change in mean BP from baseline through SS. Of note, the mean BP rises over the initial 45 minutes or so of the TSS and then plateaus consistent with the pharmacokinetics of AVP. The AVP dose did not have a statistically significant effect on the change in mean BP (P = .28). When comparing the initial AVP exposure to subsequent infusions, the change in mean BP was greater for the initial AVP infusion than for the subsequent infusions (P = .003).

Confounders and BP Responsiveness

The association between concurrent interventions and BP response was assessed. The modified VIS medians for the 3 epochs were 6.6 (baseline), 6.5 (TSS), and 6.5 (SS). There were no significant changes in the modified VIS over the 3 epochs (P = .13), and there was no association between change in VIS and BP response (P = .53). Twenty of the 142 infusions (14%) received 1 or more normal saline or alburnin boluses. There was no association between normal saline or alburnin boluses and BP response (P = .53 and P = .77, respectively). Five of 142 infusions received a calcium bolus. We did not find an association between calcium boluses and blood pressure response using ANOVA analysis (P = .76).

Analysis of All Shunt Types

For all patients, there was a significant increase in BP and CPP (Table 2). By the end of the SS, the systolic BP,
diastolic BP, mean BP, and CPP had increased by 4.1 ± 9.6 mm Hg, 1.8 ± 4.6 mm Hg, 2.5 ± 6.3 mm Hg, and 2.0 ± 4.7 mm Hg, respectively (P < .001 for all). There was no change in mean BP in 32% of infusions; the mean BP increased by 0 to 5 mm Hg in 34% of infusions, by 5 to 10 mm Hg in 25% of infusions and by > 10 mm Hg in 10% of infusions. There was a significant increase in \( \text{SaO}_2 \) and cerebral and renal oxygen extraction ratio (\( \text{O}_2\text{ER} \)) (2.5% ± 6.3%, 4.1% ± 9.6%, and 2.0% ± 4.7%; \( P < .001 \) for each) (Table 3). There was no appreciable change in the \( \text{Qp:Qs} \). Figure 2 demonstrates the change in cerebral and renal \( \text{O}_2\text{ER} \) through SS. Of note, there is a progressive increase in the cerebral and renal \( \text{O}_2\text{ER} \) over the initial 45 minutes of the TSS period, mirroring the change in mean BP.

Kendall’s correlation demonstrated a positive association between changes in BP and changes in \( \text{SaO}_2 \) (\( P < .011 \)), \( \text{Qp:Qs} \) (\( P = .011 \)), cerebral \( \text{O}_2\text{ER} \) (\( P = .041 \)), and renal \( \text{O}_2\text{ER} \) (\( P < .001 \)).

### Analysis According to Shunt Subtype

Of the 64 patients exposed to AVP, there were 31 in the BTS group (48%) and 33 in the RVPAS group (52%). Seventy-two and 70 of the infusions occurred in BTS and RVPAS patients, respectively. The RVPAS cohort experienced a significant increase in systolic BP (4.6 ± 9.5 mm Hg; \( P = .008 \)), diastolic BP (2.5 ± 5.4 mm Hg; \( P < .001 \)), mean BP (3.2 ± 6.5 mm Hg; \( P < .001 \)), and CPP (2.7 ± 5.2 mm Hg; \( P = .001 \)) (Table 4). There was no significant change in CAP or HR. The RVPAS cohort also experienced a significant increase in \( \text{SaO}_2 \) (1.4% ± 3.8%; \( P = .011 \)), \( \text{Qp:Qs} \) (0.2 ± 0.4; \( P = .017 \)), and cerebral and renal \( \text{O}_2\text{ER} \) (4.6% ± 8.7%; \( P = .010 \), and 4.7% ± 9.4%; \( P = .014 \)) (Table 5). The BTS cohort experienced a significant increase in diastolic BP and mean BP (1.1 ± 3.8 mm Hg; \( P = .031 \) and 1.8 ± 6.2 mm Hg; \( P = .008 \)) but no significant change in systolic BP or CAP. As a result, the CPP increased significantly during the SS epoch. However, the change in CPP lost significance by the end of the SS period because the increase in diastolic BP became less significant (Table 4). There was a significant increase in HR (3.2 ± 10.0; \( P = .015 \)). There was no significant change in \( \text{SaO}_2 \), \( \text{Qp:Qs} \), or cerebral or renal \( \text{O}_2\text{ER} \) (Table 5). Figure 3 provides an overview of the results of this analysis.

### DISCUSSION

This study provides a high-fidelity assessment of the acute effects of a vasopressor on hemodynamic parameters and tissue oxygenation following the NP according to shunt type. The short half-life of AVP and the continuous capturing of hemodynamic data enabled us to evaluate the acute influence of this agent on the circulation while minimizing the influence of clinically relevant confounders.

For the entire group of patients, AVP induced a significant increase in BP and significant decrease in cerebral and renal tissue oxygenation. A Kendall’s correlation analysis demonstrated a positive association between changes in BP and changes in \( \text{SaO}_2 \), \( \text{Qp:Qs} \), and cerebral and renal

---

**TABLE 2. Changes in hemodynamic parameters for the entire cohort**

| Time (min) | mBP Mean ± SD | \( P \) value | CAP Mean ± SD | \( P \) value |
|------------|--------------|--------------|--------------|--------------|
| 60-75      | 2.5 ± 6.2    | <.001        | -0.1 ± 1.9   | .478         |
| 75-90      | 2.5 ± 6.3    | <.001        | -0.1 ± 2.0   | .461         |
| 90-105     | 2.4 ± 6.2    | <.001        | 0.0 ± 2.1    | .483         |
| 105-120    | 2.5 ± 6.3    | <.001        | 0.0 ± 2.1    | .504         |

| sBP        | Mean ± SD    | \( P \) value |            |             |
|------------|--------------|--------------|------------|------------|
| 60-75      | 4.2 ± 9.8    | <.001        | 2.2 ± 4.4  | <.001      |
| 75-90      | 4.1 ± 9.8    | <.001        | 2.1 ± 4.5  | <.001      |
| 90-105     | 4.1 ± 9.6    | <.001        | 2.0 ± 4.6  | <.001      |
| 105-120    | 4.1 ± 9.6    | <.001        | 2.0 ± 4.7  | <.001      |

| dBP        | Mean ± SD    | \( P \) value |            |             |
|------------|--------------|--------------|------------|------------|
| 60-75      | 1.8 ± 4.5    | <.001        | 1.2 ± 8.7  | .105       |
| 75-90      | 1.8 ± 4.5    | <.001        | 1.2 ± 9.0  | .116       |
| 90-105     | 1.8 ± 4.5    | <.001        | 1.1 ± 9.4  | .166       |
| 105-120    | 1.8 ± 4.6    | <.001        | 1.0 ± 9.5  | .192       |

mBP, Mean blood pressure; CAP, common arterial pressure; sBP, systolic blood pressure; CPP, coronary perfusion pressure; dBP, diastolic blood pressure; HR, heart rate.

*Values are changes in parameters with respect to their baseline values. \( P \) values are computed using 1-sample t-tests with mean equal to 0 as the null hypothesis.

---

**FIGURE 1.** Moving median and moving interquartile range (IQR) for the change in mean blood pressure (mBP) with respect to its baseline values. Arginine vasopressin infusions start at time 0. mvg, Moving.
O₂ER. Figure 2 illustrates the temporal association between rise in BP and increase in cerebral and renal O₂ER. When evaluating the response to AVP according to shunt type, the RVPAS cohort experienced a more robust vasopressor response than did the BTS group, which based on the SaO₂, Qp:Qs, and cerebral and renal O₂ER, increased Qp at the expense of Qs. The BTS cohort experienced a less significant vasopressor response to AVP with no change in pulmonary or systemic perfusion. The RVPAS group experienced a significant increase in diastolic BP and CPP throughout the entire SS period. During the initial 30 minutes of the SS period, the BTS group experienced a significant increase in diastolic BP and CPP yet continued increases in diastolic BP during the latter 30 minutes was less robust and was insufficient to overcome the oscillations in CAP.

These findings are in line with the effects of a vasopressor such as AVP on the circulation.3-9 AVP vasoconstricts systemic arterial resistance vessels, increasing SVR, and systemic arterial BP. Without a change in contractility and ventricular end diastolic volume, the ejection fraction and stroke volume decrease as BP rises.3,4 In patients with single ventricle physiology, changes in SVR and/or pulmonary VR (PVR), alter the distribution of total CO between the systemic and pulmonary circulations.5-9 As the SVR to PVR ratio increases, so too does Qp:Qs,5-9 which for a given total CO, increases Qp at the expense of Qs. It is logical to conclude that the decrease in tissue oxygenation in the RVPAS group resulted at least in part from an increase in SVR:PVR and rise in systolic BP, as the SaO₂, Qp:Qs, and cerebral and renal O₂ER increased significantly. The BTS group experienced a less robust vasopressor response to AVP and no change in Qp or Qs. The vasopressor response to AVP in this cohort was mixed, with some patients not experiencing an increase in BP. Mastropietro and colleagues11 found similar results in their analysis of patients following pediatric cardiac surgery. It is possible that the AVP dose was either inadequate or baseline neurohormonal levels influenced the response of the circulation to this exogenous vasopressor, which has been demonstrated for AVP as well as other neurohormones.

**TABLE 3. Changes in oximetric parameters for the entire cohort**

| Time (min) | SaO₂ | Mean ± SD | P value | Qp:Qs | Mean ± SD | P value |
|-----------|------|-----------|---------|-------|-----------|---------|
| 60-75     | 2.5 ± 6.2 | <.001     | -0.1 ± 1.9 | .478 |
| 75-90     | 2.5 ± 6.3 | <.001     | -0.1 ± 2.0 | .461 |
| 90-105    | 2.4 ± 6.2 | <.001     | 0.0 ± 2.1 | .483 |
| 105-120   | 2.5 ± 6.3 | <.001     | 0.0 ± 2.1 | .504 |

SaO₂, Arterial oxygen saturation; Qp:Qs, pulmonary blood flow to systemic blood flow ratio; cO₂ER, cerebral oxygen extraction ratio; rO₂ER, renal oxygen extraction ratio. *Values are changes in parameters with respect to their baseline values. |P values are computed using 1-sample t tests with mean equal to 0 as the null hypothesis.

**FIGURE 2.** Moving median and moving interquartile (IQR) range for the change in cerebral oxygen extraction ratio (cO₂ER) and renal oxygen extraction ratio (rO₂ER) with respect to their baseline values. Arginine vasopressin infusions start at time 0. mvg, Moving.
such as cortisol.\textsuperscript{12,13} Mastropietro and colleagues\textsuperscript{12} as well as Morrison and colleagues\textsuperscript{13} did not find a relationship between perioperative AVP levels and hypotension or requirement for or response to vasopressors.

It is of interest that the RVPAS group experienced a more robust vasopressor response to AVP than the BTS cohort. There are important differences in physiology between shunt types that are reflected in their baseline hemodynamic data.\textsuperscript{14,15} For the RVPAS, shunting is limited to ventricular systole. For the BTS, shunting occurs throughout the cardiac cycle, leading to diastolic runoff and a lower diastolic pressure compared with the RVPAS. Shunt caliber importantly influences the extent of shunting because studies have found marked differences in Qp:Qs with changes in the caliber of shunt from 1 size to the next.\textsuperscript{14-16} The difference in the response between the RVPAS and BTS to AVP following the NP warrants further investigation. The clinical implications of these findings and the optimal vasoactive strategy following the NP merits further investigation as well.

There are limitations to this analysis. A retrospective analysis has inherent limitations, such as the influence of interventions temporally associated with the AVP infusion that may have influenced the circulation. We did not find a significant relationship between VIS and BP response. Nor did we find a significant relationship between the

| Time (min) | RVPAS  | BTS  |
|------------|--------|------|
| RVPAS      |        |      |
| P value    |        |      |
| 60-75      | 2.4 ± 6.6 | 2.7 ± 6.1 |
| 75-90      | 2.7 ± 6.5 | 2.4 ± 6.2 |
| 90-105     | 2.9 ± 6.4 | 2.0 ± 6.2 |
| 105-120    | 3.2 ± 6.5 | 1.8 ± 6.2 |

Values are presented as mean ± SD. mBP, Mean blood pressure; CAP, common arterial pressure; RVPAS, Right ventricular to pulmonary artery shunt; BTS, Blalock-Taussig shunt; HR, heart rate; bpm; dBP, diastolic blood pressure; CPP, coronary perfusion pressure; mBP, mean blood pressure; SaO2, Arterial oxygen saturation; Qp:Qs, pulmonary blood flow to systemic blood flow ratio; RVPAS, Right ventricular to pulmonary artery shunt; BTS, Blalock-Taussig shunt; cO2ER, cerebral oxygen extraction ratio; rO2ER, renal oxygen extraction ratio. *Values are changes in parameters with respect to their baseline. | P value | BTS  | P value |
| 60-75      | 2.0 ± 5.3 | 1.7 ± 3.8 | -1.0 ± 9.2 |
| 75-90      | 2.2 ± 5.3 | 1.5 ± 3.9 | -1.1 ± 9.3 |
| 90-105     | 2.4 ± 5.3 | 1.2 ± 3.9 | -1.2 ± 9.5 |
| 105-120    | 2.5 ± 5.4 | <.001 | -1.3 ± 9.3 |

Values are presented as mean ± SD. mBP, Mean blood pressure; CAP, common arterial pressure; RVPAS, Right ventricular to pulmonary artery shunt; BTS, Blalock-Taussig shunt; HR, heart rate; bpm; dBP, diastolic blood pressure; CPP, coronary perfusion pressure; mBP, mean blood pressure; SaO2, Arterial oxygen saturation; Qp:Qs, pulmonary blood flow to systemic blood flow ratio; RVPAS, Right ventricular to pulmonary artery shunt; BTS, Blalock-Taussig shunt; cO2ER, cerebral oxygen extraction ratio; rO2ER, renal oxygen extraction ratio. *Values are changes in parameters with respect to their baseline. | P value | BTS  | P value |
| 60-75      | 1.2 ± 3.9 | 1.1 ± 3.2 | 0.3 ± 0.5 |
| 75-90      | 1.3 ± 3.8 | 0.9 ± 3.3 | 0.3 ± 0.5 |
| 90-105     | 1.4 ± 3.9 | 0.6 ± 3.3 | 0.2 ± 0.5 |
| 105-120    | 1.4 ± 3.8 | 0.4 ± 3.4 | 0.2 ± 0.4 |

Values are presented as mean ± SD. SaO2, Arterial oxygen saturation; Qp:Qs, pulmonary blood flow to systemic blood flow ratio; RVPAS, Right ventricular to pulmonary artery shunt; BTS, Blalock-Taussig shunt; cO2ER, cerebral oxygen extraction ratio; rO2ER, renal oxygen extraction ratio. *Values are changes in parameters with respect to their baseline. | P value | BTS  | P value |
| 60-75      | 5.3 ± 8.5 | 3.9 ± 9.3 | 2.9 ± 8.2 |
| 75-90      | 5.3 ± 8.5 | 3.5 ± 9.5 | 3.5 ± 8.6 |
| 90-105     | 4.9 ± 8.7 | 2.6 ± 9.3 | 4.2 ± 9.0 |
| 105-120    | 4.6 ± 8.7 | 2.1 ± 9.2 | 4.7 ± 9.4 |

Values are presented as mean ± SD. SaO2, Arterial oxygen saturation; Qp:Qs, pulmonary blood flow to systemic blood flow ratio; RVPAS, Right ventricular to pulmonary artery shunt; BTS, Blalock-Taussig shunt; cO2ER, cerebral oxygen extraction ratio; rO2ER, renal oxygen extraction ratio. *Values are changes in parameters with respect to their baseline. | P value | BTS  | P value |
| 60-75      | 5.3 ± 8.5 | 3.9 ± 9.3 | 2.9 ± 8.2 |
| 75-90      | 5.3 ± 8.5 | 3.5 ± 9.5 | 3.5 ± 8.6 |
| 90-105     | 4.9 ± 8.7 | 2.6 ± 9.3 | 4.2 ± 9.0 |
| 105-120    | 4.6 ± 8.7 | 2.1 ± 9.2 | 4.7 ± 9.4 |

Values are presented as mean ± SD. SaO2, Arterial oxygen saturation; Qp:Qs, pulmonary blood flow to systemic blood flow ratio; RVPAS, Right ventricular to pulmonary artery shunt; BTS, Blalock-Taussig shunt; cO2ER, cerebral oxygen extraction ratio; rO2ER, renal oxygen extraction ratio. *Values are changes in parameters with respect to their baseline. | P value | BTS  | P value |
| 60-75      | 5.3 ± 8.5 | 3.9 ± 9.3 | 2.9 ± 8.2 |
| 75-90      | 5.3 ± 8.5 | 3.5 ± 9.5 | 3.5 ± 8.6 |
| 90-105     | 4.9 ± 8.7 | 2.6 ± 9.3 | 4.2 ± 9.0 |
| 105-120    | 4.6 ± 8.7 | 2.1 ± 9.2 | 4.7 ± 9.4 |

Values are presented as mean ± SD. SaO2, Arterial oxygen saturation; Qp:Qs, pulmonary blood flow to systemic blood flow ratio; RVPAS, Right ventricular to pulmonary artery shunt; BTS, Blalock-Taussig shunt; cO2ER, cerebral oxygen extraction ratio; rO2ER, renal oxygen extraction ratio. *Values are changes in parameters with respect to their baseline. | P value | BTS  | P value |
| 60-75      | 5.3 ± 8.5 | 3.9 ± 9.3 | 2.9 ± 8.2 |
| 75-90      | 5.3 ± 8.5 | 3.5 ± 9.5 | 3.5 ± 8.6 |
| 90-105     | 4.9 ± 8.7 | 2.6 ± 9.3 | 4.2 ± 9.0 |
| 105-120    | 4.6 ± 8.7 | 2.1 ± 9.2 | 4.7 ± 9.4 |
administration of intravascular volume and BP response, with <15% of infusions accompanied by volume expansion. Further, one would expect volume expansion and/or vasoactive support other than AVP to either maintain or increase Qs, and the linear regression analysis and correlation analysis found a positive relationship between change in BP and SaO2, Qp:Qs, and cerebral and renal O2ER. All patients were on a continuous infusion of calcium to maintain an ionized calcium level >1.3 mmol/L. We did not find an association between calcium boluses and BP response.

All patients following cardiac surgery are monitored with the Medtronic INVOS 7100 NIRS oximeter; however, intermittent connectivity between the INVOS monitor and the Sickbay platform for a minority of patients led to incomplete data capture. Cerebral NIRS oximetry relies on a proprietary algorithm to derive tissue oxygenation. Studies have demonstrated a good correlation between cerebral NIRS-derived oxygen saturations and superior vena cava and jugular saturations within patients. Particularly relevant to this analysis, studies have also found NIRS oximetry to be highly accurate as a within-subject trend monitor. In this analysis, each patient served as his or her own control, with SS NIRS oximetry data compared with baseline values for each patient. In line with other published studies, we used an assumed value of 99% for the pulmonary venous oxygen saturation when determining the relative change in Qp:Qs for each patient. We did not assess lactate levels as a surrogate for tissue oxygenation.
oxygenation because the levels were randomly assessed relative to our stated study periods (baseline, time to steady state, and steady state).

CONCLUSIONS

We found that patients undergoing the NP experienced a significant vasopressor response to AVP, which varied according to shunt type. The RVPAS cohort experienced a more robust vasopressor response than the BTS group, which was associated with a significant increase in pulmonary perfusion and decrease in cerebral and renal perfusion. The BTS group experienced a less significant vasopressor response to AVP and no change in pulmonary or systemic perfusion. The influence of the vasopressor response to AVP following the NP on cerebral and renal tissue oxygenation may have implications on clinical outcomes that require further study.

Conflict of Interest Statement

The authors reported no conflicts of interest.

The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have disclosed conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest.

References

1. Burton GL, Kaufman J, Goot BH, da Cruz EM. The use of arginine vasopressin in neonates following the Norwood procedure. Cardiol Young. 2011;21:536-44.
2. Alten JA, Borasino S, Toms R, Law MA, Moellinger A, Dabal RJ. Early initiation of arginine vasopressin infusion in neonates after complex cardiac surgery. Pediatr Crit Care Med. 2012;13:300-4.
3. Walley KR. Left ventricular function: time-varying elastance and left ventricular aortic coupling. Crit Care. 2016;20:270-81.
4. Bastos MB, Burkhoff D, Maly J, Daemen J, den Uil CA, Ameloot K. Invasive left ventricle pressure-volume analysis: overview and practical clinical implications. Eur Heart J. 2020;41:1286-97.
5. Barnea O, Santamore WP, Rossi A, Santamore WP, Austin EH III. A noninvasive estimation of mixed venous oxygen saturation in neonates after the Norwood procedure. J Thorac Cardiovasc Surg. 2008;135:83-90.
6. Migliavacca F, Pennati G, Dubini G, Fumero R, Pietrabissa R, Urselli L, et al. Arginine vasopressin in children undergoing cardiopulmonary bypass. Cardiol Young. 2010;20:135-40.
7. Alten JA, Borasino S, Toms R, Law MA, Moellinger A. Early initiation of arginine vasopressin infusion in neonates after complex cardiac surgery. Pediatr Crit Care Med. 2012;13:300-4.
8. Tweedell JS, Hoffman GM, Fedderly RY, Berger S, Thomas JP Jr, Ghanayem NS, et al. Phenoxybenzamine improves systemic oxygen delivery after the Norwood procedure. Ann Thorac Surg. 1999;67:161-8.
9. Li J, Zhang G, McCrindle BW, Holtby H, Humphl T, Cai S, et al. Profiles of hemodynamics and oxygen transport derived by using continuous measured oxygen consumption after the Norwood procedure. J Thorac Cardiovasc Surg. 2007;133:441-8.
10. Gaiés MG, Jeffries HE, Niebler RA, Pasquale SK, Donohue JE, Yu S, et al. Vasopressive-inotropic score (VIS) is associated with outcome after infant cardiac surgery: an analysis from the pediatric cardiac critical care consortium (PC4) and virtual PICU system registries. Pediatr Crit Care Med. 2014;15:529-37.
11. Mastropietro CW, Davalo MC, Seshadri S, Walters HL III, Delius RE. Clinical response to arginine vasopressin therapy after paediatric cardiac surgery. Cardiol Young. 2013;23:387-93.
12. Mastropietro CW, Rossi NF, Clark JA, Chen H, Walters H III, Delius R, et al. Relative deficiency of arginine vasopressin in children after cardiopulmonary bypass. Crit Care Med. 2010;38:2052-8.
13. Morrison WE, Simone S, Conway D, Tumulty J, Johnson C, Cardarelli M. Levels of vasopressin in children undergoing cardiopulmonary bypass. Cardiol Young. 2008;18:135-40.
14. Watanabe N, Anagnostopoulos PV, Shinkawa T, Johnson N, Azakie A. Size of the right ventricle-to-pulmonary artery conduit impacts mid-term outcome after the Norwood procedure in patients weighing less than 3 kg. J Thorac Cardiovasc Surg. 2012;144:1091-4.
15. Sinha R, Chen P, Sam R, Dodge-Khatami A, Salazar JD. Results of less than 5 mm right ventricle-pulmonary artery conduits in single ventricle palliation. Ann Thorac Surg. 2021;111:2028-32.
16. Bove EL, Migliavacca F, de Leval M, Balossino R, Pennati G, Lloyd TR, et al. Use of mathematical modeling to compare and predict hemodynamic effects of the modified Blalock-Taussig and right ventricle-pulmonary artery shunts for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 2012;136:1312-20.
17. Li J, Zhang G, Holtby H, Goerupian A-M, Cai S, Humphl T, et al. The influence of systemic hemodynamics and oxygen transport on cerebral oxygen saturation in neonates after the Norwood procedure. J Thorac Cardiovasc Surg. 2008;135:83-90.
18. Kirshbom PM, Forbess JM, Kogon BE, Simesic JM, Kim DW, Raviele AA, et al. Cerebral near infrared spectroscopy is a reliable marker of systemic perfusion in awake single ventricle children. Pediatr Crit Care Med. 2007;8:42-5.
19. Ranucci M, Iggo G, La Torre TD, Romitti F, Conis D, Carlucci C. Near-infrared spectroscopy correlates with continuous superior vena cava oxygen saturation in pediatric cardiac surgery patients. Pediatr Anesth. 2008;18:1163-9.
20. Tortoriello TA, Stayer SA, Mott AR, McKenzie ED, Fraser CD, Andropoulos DB, et al. A noninvasive estimation of mixed venous oxygen saturation using near-infrared spectroscopy in awake single ventricle children. Pediatr Crit Care Med. 2011;12:350-6.
21. Hoffman GM, Bove EL, Migliavacca F, de Leval M, Balossino R, Pennati G, Lloyd TR, et al. Use of mathematic modeling to compare and predict hemodynamic effects of the modified Blalock-Taussig and right ventricle-pulmonary artery conduits in single ventricle palliation. J Thorac Cardiovasc Surg. 2021;161:529-37.

Key Words: Norwood procedure, single ventricle, vasopressin, afterload, pulmonary to systemic perfusion ratio, oxygen delivery, near infrared spectroscopy oximetry.